Literature DB >> 8535339

Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET.

P S Conti1, M M Alauddin, J R Fissekis, B Schmall, K A Watanabe.   

Abstract

Rapid in vivo catabolism limits the use of currently available radiotracers used in tumor proliferation studies with PET. This is manifested by the need to develop complex mathematical models to interpret kinetic and metabolite data obtained from imaging studies with agents such as carbon-11 labeled thymidine. A potential carbon-11 labeled radiotracer for cellular proliferation, 2'-fluoro-5-([11C]-methyl)-1-beta-D-arabinofuranosyluracil (FMAU), has been prepared using a previously described method for preparation of [11C]methyl-thymidine where selective alkylation of a pyrimidyl dianion is accomplished with [11C]methyl iodide at the 5-position of the pyrimidine ring. FMAU shares many in vivo characteristics of thymidine, including cellular transport, phosphorylation by mammalian kinase, and incorporation into DNA. Most importantly, in vivo catabolism of FMAU is limited, potentially yielding simplified kinetic models for determination of cellular proliferation with positron emission tomography.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8535339     DOI: 10.1016/0969-8051(95)00017-r

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  17 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

Review 3.  Positron emission tomography imaging of cancer biology: current status and future prospects.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 4.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

5.  PET/CT in prostate cancer: non-choline radiopharmaceuticals.

Authors:  P Castellucci; H Jadvar
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-08       Impact factor: 2.346

6.  Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer.

Authors:  Haihao Sun; Andrew Sloan; Thomas J Mangner; Ulka Vaishampayan; Otto Muzik; Jerry M Collins; Kirk Douglas; Anthony F Shields
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01       Impact factor: 9.236

7.  A new nucleoside analogue with potent activity against mutant sr39 herpes simplex virus-1 (HSV-1) thymidine kinase (TK).

Authors:  G S M Sundaram; Scott E Harpstrite; Jeff Lung-Fa Kao; Silvia D Collins; Vijay Sharma
Journal:  Org Lett       Date:  2012-07-05       Impact factor: 6.005

Review 8.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.

Authors:  Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

9.  MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.

Authors:  Xiaoyuan Chen; Ryan Park; Yingping Hou; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; Michel Tohme; James R Bading; Walter E Laug; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-29       Impact factor: 9.236

10.  Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer.

Authors:  Anthony F Shields; Jawana M Lawhorn-Crews; David A Briston; Sajad Zalzala; Shirish Gadgeel; Kirk A Douglas; Thomas J Mangner; Lance K Heilbrun; Otto Muzik
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.